...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Lung cancer: Journal of the International Association for the Study of Lung Cancer >Vinorelbine plus cisplatin versus cisplatin plus vindesine and mitomycin C in stage IIIB-IV non-small cell lung carcinoma: a prospective randomized study.
【24h】

Vinorelbine plus cisplatin versus cisplatin plus vindesine and mitomycin C in stage IIIB-IV non-small cell lung carcinoma: a prospective randomized study.

机译：Vinorelbine +顺铂与顺铂+长春地辛和丝裂霉素C在IIIB-IV阶段非小细胞肺癌:一个未来随机研究。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

PURPOSE: To compare a regimen of vinorelbine and cisplatin (VC) to the combination of mitomycin, vindesine, and cisplatin (MVP) in patients with stage IIIB or stage IV non-small cell lung cancer (NSCLC). The main endpoits were analysis of objective response rates, toxicity, time to progression, and overall survival. PATIENTS AND METHODS: 247 eligible patients were randomized to receive (a) vinorelbine 25 mg/m(2) intravenous bolus on days 1and 8 plus cisplatin 100 mg/m(2) on day 1 every 4 weeks, or (b) mitomycin c 8 mg/m(2) i.v. on day 1, vindesine 3 mg/m(2) i.v. on days 1, 8, 15 and 22, plus cisplatin 100 mg/m(2) on day 1 every 4 weeks. In subsequent cycles vindesine was given every other week. For both treatments a maximum of six cycles was planned. Patients with performance status 0-2 according to the ECOG scale were enrolled. Response and toxicity were evaluated according to the WHO criteria. Analysis of clinical efficacy was performed according to an intent-to-treat analysis. RESULTS: No statistically significant differences in clinical efficacy were observed between the two chemotherapy regimens. The overall objective response rates were 39% (95% CL, 31-49%) in the VC arm and 42% (95% CL, 33-51%) in the MVP arm (P=0.13). Median time to progression was 4.2 and 4.5 months for the MVP arm and the VC arm, respectively. Median overall survival was 7 months in the VC arm and 8 months in the MVP one (log-rank test, P=0.898). These differences were not statistically significant. However, leukopenia and thrombocytopenia were significantly higher in the MVP arm than in the VC (P=0.0001; P=0.0002). Grade 3 alopecia was more frequent in the MVP arm than in the VC one (P<0.001), which was associated with higher rate of phlebitis (P=0.037). CONCLUSION: Data achieved in this study suggest that the vinorelbine-cisplatin doublet is similar to the three-drug MVP regimen in term of overall response rate, time to progressive disease, and overall survival. However, hematological toxicity and alopecia are more frequent and severe in the MVP regimen which therefore appears to be less tolerable than the VC regimen. The combination of vinorelbine and cisplatin may be considered as a reference treatment for future studies on the treatment of advanced NSCLC.
机译：目的:比较vinorelbine和方案顺铂(VC)丝裂霉素的结合,长春地辛,顺铂(MVP)的患者阶段希望或四期非小细胞肺癌(NSCLC)。客观反应率、毒性、时间进展,整体存活率。方法:247名符合条件的患者被随机分配收到(a) vinorelbine 25毫克/米(2)静脉注射丸在天1和8 +顺铂100毫克/米(2)每4周1天,或者(b)丝裂霉素c 8毫克/米(2)输液1天,长春地辛3毫克/米(2)注射。1天8 +顺铂100。15 - 22日毫克/米(2)每4周1天。每隔一周周期长春地辛了。两种治疗最多6个周期计划。根据ECOG规模为。反应和毒性进行评估世界卫生组织的标准。根据执行intent-to-treat吗分析。观察临床疗效的差异之间的两个化疗方案。总体客观反应率分别为39% (95%CL, 31 - 49%)在VC的胳膊,42%(95%氯,在MVP的手臂33 - 51%)(P = 0.13)。MVP进展4.2和4.5个月手臂和VC的手臂,分别。生存是7个月的VC手臂和8个月在MVP(生存率较,P = 0.898)。差异没有统计学意义。然而,白细胞减少和血小板减少MVP的手臂比更高VC (P = 0.0001;更频繁的MVP的手臂的VC(P < 0.001),与更高的速率有关静脉炎(P = 0.037)。在这项研究中表明vinorelbine-cisplatin紧身上衣是相似的三种药物MVP方案的整体响应速度,时间进行性疾病,总体生存率。和中更频繁和严重的脱发MVP方案,因此似乎更少可容忍的风险投资方案。vinorelbine和顺铂可能被视为一种未来研究的参考治疗治疗晚期非小细胞肺癌。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号